Skip to main navigation
Tactile Medical
  • About Lymphedema
    • Overview
    • Signs & Symptoms
    • Treatment
    • Management
  • Products
    • Overview
    • FLEXITOUCH® system
    • Entre™ System
    • Actitouch® System
    • Clinical Evidence
  • Patients
    • Overview
    • Signs & Symptoms
    • Patient Testimonials
    • Lymphedema Partners
  • Healthcare Professionals
    • Overview
    • Virtual Learning
    • Clinician Perspectives
    • Health Plan Coverage
    • Veterans Affairs
    • Clinical Evidence
    • Professional Affiliations
    • Educational Resources
  • Investors
    • News
    • Events & Webcasts
    • Stock Information
    • Annual Reports & SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Investor Contacts
  • About Us
    • Who We Are
    • Leadership
    • News
    • Careers
Patient Portal
Select Page

News Release Details

Tactile Systems Announces Closing of Initial Public Offering

August 2, 2016 at 4:06 PM EDT
PDF Version

MINNEAPOLIS, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company that develops innovative medical devices for the treatment of chronic diseases at home, announced today the closing of its initial public offering of 4,120,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.  All shares of the common stock in this offering are being sold by Tactile Medical.  Tactile Medical’s common stock began trading on The NASDAQ Global Market on July 28, 2016 under the ticker symbol “TCMD.”

Piper Jaffray & Co., William Blair & Company, L.L.C, and Canaccord Genuity Inc. acted as joint book-running managers for the offering. BTIG, LLC acted as co-manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on July 27, 2016. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com, or William Blair & Company L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, by telephone at (800) 621-0867, or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Investor Inquiries:

Mike Piccinino
Managing Director
Westwicke Partners
(443) 213-0500
investorrelations@tactilemedical.com

Media Inquiries:

Kristen Weaver
Director of Marketing Communications
Tactile Medical
(612) 355-5116

Tactile Systems Technology
  • RSS Feeds
  • Email Alerts
  • Investor Contacts
  • Print Page
  • E-mail Page
Logo


Tactile Systems Technology, Inc. BBB Business Review
  • About Lymphedema
  • Products
  • Patients
  • Healthcare Professionals
  • Investors
  • About Us
  • Careers
  • Pay My Bill
  • Educational Resources
  • Patient Contact Us
  • Clinician Contact Us
  • Forms
  • Media Resources
  • Privacy Statement
  • California Privacy Notice
  • Privacy Line: 833.382.2845 ext. 55211
  • Terms & Conditions
  • Warranty & Return Policies
3701 Wayzata Blvd, Suite 300
Minneapolis, MN 55416 USA

Phone: 612.355.5100
Toll-free: 866.435.3948
Fax: 866.435.3949
facebook linkedin twitter youTube
Flexitouch, Actitouch, Entre and HEALING RIGHT AT HOME are all trademarks or registered trademarks of Tactile Medical.
D/N500187-000-00 Rev. J 11/2017